Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically documented diagnosis of invasive breast cancer that is locally advanced or metastatic~* Previous anthracycline containing chemotherapy~* Presence of a certain protein on the cell surface (c-kit (CD117) and /or PDGF-receptor)~* Preferably tumor samples should be taken within 6 weeks of study entry. Most recent primary tumor tissue has to be available for analysis~* Acceptable health status (Eastern Cooperative Oncology Group \[ECOG\]-performance status 0,1, 2 or 3)~Exclusion criteria: (for the second-line therapy)~* Patient with Grade III/IV cardiac problems (i.e., congestive heart failure, myocardial infarction within 6 months of study) and with severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).~* Patient has a known brain metastasis, chronic liver disease (i.e., chronic active hepatitis, and cirrhosis) and diagnosis of (HIV) infection.~* Patient received chemotherapy within 4 weeks prior to study entry, unless the disease is rapidly progressing.~* Patient previously received radiotherapy to ≥ 25 % of the bone marrow and had a major surgery within 2 weeks prior to study entry.~* Patient received either Vinorelbine or Imatinib in previous treatment regimens~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib + Vinorelbine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).